IRADIMED CORPORATION (NASDAQ:IRMD) shareholders are probably feeling a little disappointed, since its shares fell 4.1% to US$48.30 in the week after its latest third-quarter results. It looks like a credible result overall - although revenues of US$18m were in line with what the analysts predicted, IRADIMED surprised by delivering a statutory profit of US$0.40 per share, a notable 14% above expectations. Earnings are an important time for investors, as they can track a company's performance, look at what the analysts are forecasting for next year, and see if there's been a change in sentiment towards the company. We thought readers would find it interesting to see the analysts latest (statutory) post-earnings forecasts for next year.

Check out our latest analysis for IRADIMED

Following the latest results, IRADIMED's twin analysts are now forecasting revenues of US$80.7m in 2025. This would be a meaningful 13% improvement in revenue compared to the last 12 months. Per-share earnings are expected to accumulate 9.2% to US$1.61. In the lead-up to this report, the analysts had been modelling revenues of US$80.4m and earnings per share (EPS) of US$1.62 in 2025. The consensus analysts don't seem to have seen anything in these results that would have changed their view on the business, given there's been no major change to their estimates.

With the analysts reconfirming their revenue and earnings forecasts, it's surprising to see that the price target rose 14% to US$60.00. It looks as though they previously had some doubts over whether the business would live up to their expectations.

One way to get more context on these forecasts is to look at how they compare to both past performance, and how other companies in the same industry are performing. It's pretty clear that there is an expectation that IRADIMED's revenue growth will slow down substantially, with revenues to the end of 2025 expected to display 10% growth on an annualised basis. This is compared to a historical growth rate of 17% over the past five years. Juxtapose this against the other companies in the industry with analyst coverage, which are forecast to grow their revenues (in aggregate) 8.2% per year. So it's pretty clear that, while IRADIMED's revenue growth is expected to slow, it's still expected to grow faster than the industry itself.

The Bottom Line

The most obvious conclusion is that there's been no major change in the business' prospects in recent times, with the analysts holding their earnings forecasts steady, in line with previous estimates. Fortunately, they also reconfirmed their revenue numbers, suggesting that it's tracking in line with expectations. Additionally, our data suggests that revenue is expected to grow faster than the wider industry. There was also a nice increase in the price target, with the analysts clearly feeling that the intrinsic value of the business is improving.